News · 26 weeks49-85%
2026-03-012026-08-23
Mix2590d
- SEC Filings12(48%)
- Insider7(28%)
- Other3(12%)
- Earnings3(12%)
Latest news
25 items- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECAmendment: MiMedx Group Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K/A - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECMiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- PRMIMEDX Announces Second Quarter 2026 Operating & Financial ResultsReports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "During the second quarter, we delivered another strong performance in our Surgical franchise, with 15% year-over-year revenue growth balanced across our sheet and particulate products. Our sustained momentum in several Su
- SECSEC Form 10-Q filed by MiMedx Group Inc10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECMiMedx Group Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- PRMIMEDX to Acquire Sanara MedTechTransformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm EDT MARIETTA, Ga. and FORT WORTH, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") and Sanara MedTech Inc. ("Sanara," "Sanara MedTech") (NASDAQ:SMTI) today a
- PRMIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, July 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13761338 A replay of the webcast will be available for approximately 30 days on the Company’s website
- INSIDERChief Financial Officer Doug Rice covered exercise/tax liability with 12,749 shares, decreasing direct ownership by 3% to 399,566 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 19,820 shares, decreasing direct ownership by 6% to 309,630 units (SEC Form 4) (withholding tax)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- SECMiMedx Group Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- PRThe Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding ItIssued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow itself. One newly public name just took a concrete step toward proving it. NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — For most of medical history, the body's inability to regrow lost tissue has been treated as a fact to be managed rather than a problem to be solved. When skin, bone, or soft tissue is destroyed by injury, surgery, disease, or age, the standard of care has largely been about coverage and replacement — grafts, implants, fillers,
- INSIDERDirector Bierman James L was granted 50,913 shares, increasing direct ownership by 24% to 263,684 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERDirector Puhy Dorothy E was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERDirector Newton Todd was granted 50,913 shares, increasing direct ownership by 12% to 463,684 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERDirector Hawkins William A was granted 50,913 shares, increasing direct ownership by 25% to 254,931 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERDirector Olson Tiffany was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- PRA Fresh FDA Catalyst Is Putting Regenerative Wound Care in FocusNEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (NASDAQ:CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further into manufacturing scale-up and regulatory preparation as it works toward a planned first-quarter 2027 510(k) submission. Companies mentioned: Conexeu Scien
- PRThe Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement PartsIssued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome
MDXG FAQ
6 questionsWhat does MiMedx Group Inc do?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective...Where does MDXG stock trade?
MiMedx Group Inc (MDXG) is listed on NASDAQ.What sector and industry is MDXG in?
MiMedx Group Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MDXG?
MiMedx Group Inc has had 7 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $1000.00 price target on 2026-02-23. Recent price targets range from $700.00 to $2300.00.What companies are similar to MDXG?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MDXG side-by-side with any of them on Quantisnow.How can I track MDXG on Quantisnow?
Quantisnow aggregates MiMedx Group Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDXG to receive live email and push alerts on every new disclosure.